Publications by authors named "Daniela Strosova"
A poor patient adherence often limits the real-world effectiveness of an oral disease-modifying therapy (DMT) for multiple sclerosis (MS). In the present study, we aimed to map patient preferences, attitudes toward treatment, and quality of life to identify the predictors of non-adherence to teriflunomide. This was a single-arm, non-interventional, multicenter study (Czech Act 378/2007 Coll.
View Article and Find Full Text PDFThe prevalence of allergic rhinoconjunctivitis (AR) has been increasing over the years, and allergen immunotherapy (AIT) remains the only disease-modifying treatment. However, cost-effectiveness data remain scarce. In this single-arm, noninterventional, prospective, multicenter study, we describe the effectiveness, safety and costs of subcutaneous AIT for pollen-induced allergic rhinoconjunctivitis.
View Article and Find Full Text PDFBackground: Atrial fibrillation (AF) affects 46.3 million people; its prevalence has tripled over the last 50 years. AF leads to formation of blood clots increasing four-fold the risk of a stroke.
View Article and Find Full Text PDFArticle Synopsis
- The study looked at how well a medicine called dupilumab worked for people with bad eczema (a skin condition) in the Czech Republic.
- They checked the skin and quality of life of 50 patients before starting and for a year after starting the treatment.
- The results showed that most patients saw big improvements in their skin, and the medicine was safe, with only a few mild side effects.
Background: Dupilumab has been approved to treat moderate-to-severe atopic dermatitis; however, the data in a real-world setting are still limited.
Objective: To analyze the effectiveness and safety of dupilumab.
Methods: This was a real-life Czech multicenter retrospective study from patients treated with dupilumab for severe AD.
Article Synopsis
- The study looked at how well a medicine called adalimumab works for patients with psoriasis in the Czech Republic from 2005 to 2018.
- Over 1,150 patients were treated, and many showed a big improvement in their skin condition after 12 and 96 months on the medicine.
- The study found that things like being female, being overweight, and having taken other treatments before can make the medicine work less well for some people.